Clinical implication of genome-wide profiling in diffuse large B-cell lymphoma and other subtypes of B-cell lymphoma

Javeed Iqbal, Shantaram S Joshi, Kavita N. Patel, Sofi I. Javed, Can Kucuk, Afeera Aabida, Francesco D'Amore, Kai Fu

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The differentiation of lymphoid cells is tightly regulated by transcription factors at various stages during their development. During the maturation processes, different genomic alterations or aberrations such as chromosomal translocation, mutation and deletions may occur that can eventually result in distinct biological and clinical tumors. The different differentiation stages create heterogeneity in lymphoid malignancies, which can complicate the diagnosis. The initial diagnostic scheme for lymphoid diseases was coined by Rappaport followed by Revised European and American Classification of Lymphoid Neoplasms (REAL) and World Health Organization (WHO) classifications. These classification methods were based on histological, immunophenotypic and cytogenetic markers and widely accepted by pathologists and oncologists worldwide. During last several decades, great progress has been made in understanding the etiology, pathogenesis and molecular biology of malignant lymphoma. However, detailed knowledge in the molecular mechanism of lymphomagenesis is largely unknown. New therapeutic protocols based on the new classification have been on clinical trials, but with little success. Therefore, it is imperative to understand the basic biology of the tumor at molecular level. One important approach will be to measure the activity of the tumor genome and this can partly be achieved by the measurement of whole cellular mRNA. One of the key technologies to perform a high-throughput analysis is DNA microarray technology. The genome-wide transcriptional measurement, also called gene expression profile (GEP) can accurately define the biological phenotype of the tumor. In this review, important discoveries made by genome-wide GEP in understanding the biology of lymphoma and additionally the diagnostic and prognostic value of microarrays are discussed.

Original languageEnglish (US)
Pages (from-to)72-86
Number of pages15
JournalIndian Journal of Cancer
Volume44
Issue number2
StatePublished - Apr 1 2007

Fingerprint

Lymphoma, Large B-Cell, Diffuse
B-Cell Lymphoma
Genome
Neoplasms
Transcriptome
Lymphoma
Technology
Genetic Translocation
Sequence Deletion
Oligonucleotide Array Sequence Analysis
Cytogenetics
Molecular Biology
Transcription Factors
Clinical Trials
Lymphocytes
Phenotype
Messenger RNA

Keywords

  • Classification
  • Diffuse large B-cell lymphomas
  • Gene expression profiling
  • Prognosis
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology

Cite this

Clinical implication of genome-wide profiling in diffuse large B-cell lymphoma and other subtypes of B-cell lymphoma. / Iqbal, Javeed; Joshi, Shantaram S; Patel, Kavita N.; Javed, Sofi I.; Kucuk, Can; Aabida, Afeera; D'Amore, Francesco; Fu, Kai.

In: Indian Journal of Cancer, Vol. 44, No. 2, 01.04.2007, p. 72-86.

Research output: Contribution to journalArticle

Iqbal, Javeed ; Joshi, Shantaram S ; Patel, Kavita N. ; Javed, Sofi I. ; Kucuk, Can ; Aabida, Afeera ; D'Amore, Francesco ; Fu, Kai. / Clinical implication of genome-wide profiling in diffuse large B-cell lymphoma and other subtypes of B-cell lymphoma. In: Indian Journal of Cancer. 2007 ; Vol. 44, No. 2. pp. 72-86.
@article{3b304bf7533d42ff908cde2b54f94af9,
title = "Clinical implication of genome-wide profiling in diffuse large B-cell lymphoma and other subtypes of B-cell lymphoma",
abstract = "The differentiation of lymphoid cells is tightly regulated by transcription factors at various stages during their development. During the maturation processes, different genomic alterations or aberrations such as chromosomal translocation, mutation and deletions may occur that can eventually result in distinct biological and clinical tumors. The different differentiation stages create heterogeneity in lymphoid malignancies, which can complicate the diagnosis. The initial diagnostic scheme for lymphoid diseases was coined by Rappaport followed by Revised European and American Classification of Lymphoid Neoplasms (REAL) and World Health Organization (WHO) classifications. These classification methods were based on histological, immunophenotypic and cytogenetic markers and widely accepted by pathologists and oncologists worldwide. During last several decades, great progress has been made in understanding the etiology, pathogenesis and molecular biology of malignant lymphoma. However, detailed knowledge in the molecular mechanism of lymphomagenesis is largely unknown. New therapeutic protocols based on the new classification have been on clinical trials, but with little success. Therefore, it is imperative to understand the basic biology of the tumor at molecular level. One important approach will be to measure the activity of the tumor genome and this can partly be achieved by the measurement of whole cellular mRNA. One of the key technologies to perform a high-throughput analysis is DNA microarray technology. The genome-wide transcriptional measurement, also called gene expression profile (GEP) can accurately define the biological phenotype of the tumor. In this review, important discoveries made by genome-wide GEP in understanding the biology of lymphoma and additionally the diagnostic and prognostic value of microarrays are discussed.",
keywords = "Classification, Diffuse large B-cell lymphomas, Gene expression profiling, Prognosis, Targeted therapy",
author = "Javeed Iqbal and Joshi, {Shantaram S} and Patel, {Kavita N.} and Javed, {Sofi I.} and Can Kucuk and Afeera Aabida and Francesco D'Amore and Kai Fu",
year = "2007",
month = "4",
day = "1",
language = "English (US)",
volume = "44",
pages = "72--86",
journal = "Indian Journal of Cancer",
issn = "0019-509X",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "2",

}

TY - JOUR

T1 - Clinical implication of genome-wide profiling in diffuse large B-cell lymphoma and other subtypes of B-cell lymphoma

AU - Iqbal, Javeed

AU - Joshi, Shantaram S

AU - Patel, Kavita N.

AU - Javed, Sofi I.

AU - Kucuk, Can

AU - Aabida, Afeera

AU - D'Amore, Francesco

AU - Fu, Kai

PY - 2007/4/1

Y1 - 2007/4/1

N2 - The differentiation of lymphoid cells is tightly regulated by transcription factors at various stages during their development. During the maturation processes, different genomic alterations or aberrations such as chromosomal translocation, mutation and deletions may occur that can eventually result in distinct biological and clinical tumors. The different differentiation stages create heterogeneity in lymphoid malignancies, which can complicate the diagnosis. The initial diagnostic scheme for lymphoid diseases was coined by Rappaport followed by Revised European and American Classification of Lymphoid Neoplasms (REAL) and World Health Organization (WHO) classifications. These classification methods were based on histological, immunophenotypic and cytogenetic markers and widely accepted by pathologists and oncologists worldwide. During last several decades, great progress has been made in understanding the etiology, pathogenesis and molecular biology of malignant lymphoma. However, detailed knowledge in the molecular mechanism of lymphomagenesis is largely unknown. New therapeutic protocols based on the new classification have been on clinical trials, but with little success. Therefore, it is imperative to understand the basic biology of the tumor at molecular level. One important approach will be to measure the activity of the tumor genome and this can partly be achieved by the measurement of whole cellular mRNA. One of the key technologies to perform a high-throughput analysis is DNA microarray technology. The genome-wide transcriptional measurement, also called gene expression profile (GEP) can accurately define the biological phenotype of the tumor. In this review, important discoveries made by genome-wide GEP in understanding the biology of lymphoma and additionally the diagnostic and prognostic value of microarrays are discussed.

AB - The differentiation of lymphoid cells is tightly regulated by transcription factors at various stages during their development. During the maturation processes, different genomic alterations or aberrations such as chromosomal translocation, mutation and deletions may occur that can eventually result in distinct biological and clinical tumors. The different differentiation stages create heterogeneity in lymphoid malignancies, which can complicate the diagnosis. The initial diagnostic scheme for lymphoid diseases was coined by Rappaport followed by Revised European and American Classification of Lymphoid Neoplasms (REAL) and World Health Organization (WHO) classifications. These classification methods were based on histological, immunophenotypic and cytogenetic markers and widely accepted by pathologists and oncologists worldwide. During last several decades, great progress has been made in understanding the etiology, pathogenesis and molecular biology of malignant lymphoma. However, detailed knowledge in the molecular mechanism of lymphomagenesis is largely unknown. New therapeutic protocols based on the new classification have been on clinical trials, but with little success. Therefore, it is imperative to understand the basic biology of the tumor at molecular level. One important approach will be to measure the activity of the tumor genome and this can partly be achieved by the measurement of whole cellular mRNA. One of the key technologies to perform a high-throughput analysis is DNA microarray technology. The genome-wide transcriptional measurement, also called gene expression profile (GEP) can accurately define the biological phenotype of the tumor. In this review, important discoveries made by genome-wide GEP in understanding the biology of lymphoma and additionally the diagnostic and prognostic value of microarrays are discussed.

KW - Classification

KW - Diffuse large B-cell lymphomas

KW - Gene expression profiling

KW - Prognosis

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=35448995311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35448995311&partnerID=8YFLogxK

M3 - Article

C2 - 17938484

AN - SCOPUS:35448995311

VL - 44

SP - 72

EP - 86

JO - Indian Journal of Cancer

JF - Indian Journal of Cancer

SN - 0019-509X

IS - 2

ER -